TimesSquare Capital Management’s Celldex Therapeutics CLDX Stock Holding History

TimesSquare Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-124,915	Closed	-$47.3M	–	250
2015 Q2	$47.3M	Buy	124,915 +1,898	+2%	+$754K	0.26%	149
2015 Q1	$51.4M	Sell	123,017 -17,686	-13%	-$6.33M	0.28%	139
2014 Q4	$38.5M	Buy	140,703 +4,967	+4%	+$1.23M	0.21%	163
2014 Q3	$26.4M	Buy	135,736 +294	+0.2%	+$64.1K	0.15%	197
2014 Q2	$33.2M	Sell	135,442 -8,886	-6%	-$2.01M	0.18%	179
2014 Q1	$38.3M	Sell	144,328 -2,506	-2%	-$960K	0.2%	168
2013 Q4	$53.3M	Buy	146,834 +22,772	+18%	+$8.77M	0.27%	136
2013 Q3	$65.9M	Buy	124,062 +45,053	+57%	+$15.4M	0.37%	93
2013 Q2	$18.5M	Buy	+79,009	New	+$15.6M	0.11%	214

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TimesSquare Capital Management's CLDX Position: Q3 2015 in Review

TimesSquare Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 124,915 shares — an estimated $47.3M sold.

TimesSquare Capital Management first reported a position in CLDX in Q2 2013 and held it in 9 quarters. The position peaked at $65.9M in Q3 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

TimesSquare Capital Management reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
TimesSquare Capital Management sold 124,915 Celldex Therapeutics shares in Q3 2015, an estimated $47.3M.
TimesSquare Capital Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 9 quarters.
TimesSquare Capital Management's Celldex Therapeutics position peaked at $65.9M in Q3 2013.
162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on TimesSquare Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.